- Home
- CLLS vs SCD Comparison
CLLS vs SCD Comparison
Compare CLLS & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | SCD |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 255.4M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | SCD |
|---|---|---|
| Price | $4.98 | $14.80 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 124.5K | 62.6K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.63% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,551,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $58.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $11.33 |
| 52 Week High | $5.48 | $15.87 |
Technical Indicators
Market Signals| Indicator | CLLS | SCD |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 52.15 |
| Support Level | $4.90 | $13.79 |
| Resistance Level | $5.35 | $14.38 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | 0.14 | 0.05 |
| Stochastic Oscillator | 85.56 | 82.20 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.